Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
    Meeting Abstract

    Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A predictive model for day-100 transplant-related mortality in AL amyloidosis
    Meeting Abstract

    Muchtar, E.; Dispenzieri, A.; Sanchorawala, V.; Hassan, H.; Mwangi, R.; Maurer, M.; Lee, H.; Qazilbash, M.; Kin, A.; Zonder, J.; more...
    Amyloid (2024)

    Fulltext@MSK | Save
  • Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2 - metastatic breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Do serum beta-D-glucan levels correspond with pneumocystis pneumonia severity among non-HIV patients?
    Meeting Abstract

    Patel, G.; Stover, D. E.; Feinstein, M. B.
    American Journal of Respiratory and Critical Care Medicine (2024)

    Fulltext@MSK | Save
  • Organizing pneumonia with surgical pathology positive for SARS-CoV2 a year after initial COVID-19 diagnosis despite negative COVID-19 PCR from nasal swabs and bronchial alveolar lavage in a lymphopenic cancer patient
    Meeting Abstract

    Dwyer, C.; Song, D.; Geyer, A. I.
    American Journal of Respiratory and Critical Care Medicine (2024)

    Fulltext@MSK | Save
  • A patient with metastatic uterine carcinosarcoma with presumed pneumonitis secondary to investigational drug Db-1303, an antibody-drug conjugate comprised of anti-HER2 monoclonal antibody linked to a DNA topoisomerase I inhibitor
    Meeting Abstract

    Dwyer, C.; Song, D.; Geyer, A. I.
    American Journal of Respiratory and Critical Care Medicine (2024)

    Fulltext@MSK | Save
  • Assessing 2024 oncology advances and looking ahead
    Editorial

    Iyengar, N. M.
    Oncology (Norwalk) (2024)

    Fulltext@MSK | Save
  • The role of ultraviolet-induced fluorescence dermatoscopy for the detection of multiple aggregated yellow-white globules in basal cell carcinoma
    Correspondence

    Navarrete-Dechent, C.; Pietkiewicz, P.; Astronave, G.; Marghoob, N. G.; Dusza, S. W.; Lorenzoni, J.; Boleira, M.; Cristopher, M.; Aguero, R.; Bustos, S.; more...
    Journal of the American Academy of Dermatology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study
    Journal Article

    Jhaveri, K. L.; Lim, E.; Jeselsohn, R.; Ma, C. X.; Hamilton, E. P.; Osborne, C.; Bhave, M.; Kaufman, P. A.; Beck, J. T.; Sanchez, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of defactinib (VS6063) in patients with tumors with NF2 Loss: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol U
    Journal Article

    Zauderer, M. G.; Jegede, O.; Jackman, D. M.; Zwiebel, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; Williams, P. M.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save